257 related articles for article (PubMed ID: 33002071)
1. J-shaped relationship between cardiovascular risk and efficacy of intensive blood pressure reduction: A post-hoc analysis of the SPRINT trial.
Attar A; Nouri F; Borazjani R; Sayadi M
PLoS One; 2020; 15(10):e0240102. PubMed ID: 33002071
[TBL] [Abstract][Full Text] [Related]
2. Effect of intensive blood pressure lowering on cardiovascular outcomes based on cardiovascular risk: A secondary analysis of the SPRINT trial.
Attar A; Sayadi M; Jannati M
Eur J Prev Cardiol; 2019 Feb; 26(3):238-245. PubMed ID: 30256671
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Risk of Harm Associated With Intensive Blood Pressure Management Among Patients With Hypertension Who Smoke: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial.
Scarpa J; Bruzelius E; Doupe P; Le M; Faghmous J; Baum A
JAMA Netw Open; 2019 Mar; 2(3):e190005. PubMed ID: 30848803
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of blood pressure-lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT).
Zhang L; Sun X; Liao L; Zhang S; Zhou H; Zhong X; Zhuang X; Liao X
J Clin Hypertens (Greenwich); 2019 Dec; 21(12):1813-1820. PubMed ID: 31670874
[TBL] [Abstract][Full Text] [Related]
5. Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials.
Basu S; Sussman JB; Rigdon J; Steimle L; Denton BT; Hayward RA
PLoS Med; 2017 Oct; 14(10):e1002410. PubMed ID: 29040268
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Hypertension: Which Goal for Which Patient?
Jarraya F
Adv Exp Med Biol; 2017; 956():117-127. PubMed ID: 27722961
[TBL] [Abstract][Full Text] [Related]
7. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial).
Soliman EZ; Ambrosius WT; Cushman WC; Zhang ZM; Bates JT; Neyra JA; Carson TY; Tamariz L; Ghazi L; Cho ME; Shapiro BP; He J; Fine LJ; Lewis CE;
Circulation; 2017 Aug; 136(5):440-450. PubMed ID: 28512184
[TBL] [Abstract][Full Text] [Related]
8. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP.
Buckley LF; Dixon DL; Wohlford GF; Wijesinghe DS; Baker WL; Van Tassell BW
Diabetes Care; 2017 Dec; 40(12):1733-1738. PubMed ID: 28947569
[TBL] [Abstract][Full Text] [Related]
9. Influence of baseline systolic blood pressure on the relationship between intensive blood pressure control and cardiovascular outcomes in the Systolic Blood Pressure Intervention Trial (SPRINT).
Sun X; Guo Y; Nie Z; Cheng J; Zhou H; Zhong X; Zhang S; Du Z; Zhuang X; Liao X
Clin Res Cardiol; 2019 Mar; 108(3):273-281. PubMed ID: 30167807
[TBL] [Abstract][Full Text] [Related]
10. Association of Estimated Pulse Wave Velocity With Survival: A Secondary Analysis of SPRINT.
Vlachopoulos C; Terentes-Printzios D; Laurent S; Nilsson PM; Protogerou AD; Aznaouridis K; Xaplanteris P; Koutagiar I; Tomiyama H; Yamashina A; Sfikakis PP; Tousoulis D
JAMA Netw Open; 2019 Oct; 2(10):e1912831. PubMed ID: 31596491
[TBL] [Abstract][Full Text] [Related]
11. Effect of Lowering Diastolic Pressure in Patients With and Without Cardiovascular Disease: Analysis of the SPRINT (Systolic Blood Pressure Intervention Trial).
Khan NA; Rabkin SW; Zhao Y; McAlister FA; Park JE; Guan M; Chan S; Humphries KH
Hypertension; 2018 May; 71(5):840-847. PubMed ID: 29581214
[TBL] [Abstract][Full Text] [Related]
12. Effects of Intensive Blood Pressure Control in Patients with Evident Cardiovascular Disease: An Investigation Using the SPRINT Study Data.
Vlachopoulos C; Terentes-Printzios D; Aznaouridis K; Ioakeimidis N; Xaplanteris P; Lazaros G; Tousoulis D
Curr Vasc Pharmacol; 2019; 17(3):298-306. PubMed ID: 29512468
[TBL] [Abstract][Full Text] [Related]
13. SPRINT trial: It's not just the blood pressure!
Berkelmans GF; Visseren FL; Jaspers NE; Spiering W; van der Graaf Y; Dorresteijn JA
Eur J Prev Cardiol; 2017 Sep; 24(14):1482-1484. PubMed ID: 28749177
[TBL] [Abstract][Full Text] [Related]
14. Serious Adverse Events Cluster in Participants Experiencing the Primary Composite Cardiovascular Endpoint: A Post Hoc Analysis of the SPRINT Trial.
Botchway A; Buhnerkempe MG; Prakash V; Al-Akchar M; Adekola B; Flack JM
Am J Hypertens; 2020 May; 33(6):528-533. PubMed ID: 31930338
[TBL] [Abstract][Full Text] [Related]
15. Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey).
Bress AP; Kramer H; Khatib R; Beddhu S; Cheung AK; Hess R; Bansal VK; Cao G; Yee J; Moran AE; Durazo-Arvizu R; Muntner P; Cooper RS
Circulation; 2017 Apr; 135(17):1617-1628. PubMed ID: 28193605
[TBL] [Abstract][Full Text] [Related]
16. Low Diastolic Blood Pressure is Not Related to Risk of First Episode of Stroke in a High-Risk Population: A Secondary Analysis of SPRINT.
Sobieraj P; Lewandowski J; Siński M; Symonides B; Gaciong Z
J Am Heart Assoc; 2019 Feb; 8(4):e010811. PubMed ID: 30744452
[TBL] [Abstract][Full Text] [Related]
17. Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events.
Bress AP; Greene T; Derington CG; Shen J; Xu Y; Zhang Y; Ying J; Bellows BK; Cushman WC; Whelton PK; Pajewski NM; Reboussin D; Beddu S; Hess R; Herrick JS; Zhang Z; Kolm P; Yeh RW; Basu S; Weintraub WS; Moran AE;
J Am Coll Cardiol; 2021 Apr; 77(16):1977-1990. PubMed ID: 33888247
[TBL] [Abstract][Full Text] [Related]
18. Heart failure and the discrepancy between trials of intensive blood pressure management: an analysis of individual patient data.
Aggarwal R; Mirzan H; Chiu N; Steinkamp J
Clin Res Cardiol; 2018 Jul; 107(7):565-569. PubMed ID: 29480390
[TBL] [Abstract][Full Text] [Related]
19. Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials.
Oikonomou EK; Spatz ES; Suchard MA; Khera R
Lancet Digit Health; 2022 Nov; 4(11):e796-e805. PubMed ID: 36307193
[TBL] [Abstract][Full Text] [Related]
20. Blood Pressure Variability Predicts Adverse Events and Cardiovascular Outcomes in Chronic Kidney Disease: A Post-Hoc Analysis of the SPRINT Trial.
Mezue K; Goyal A; Pressman GS; Horrow JC; Rangaswami J
Am J Hypertens; 2017 Dec; 31(1):48-52. PubMed ID: 28985328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
